<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04302441</url>
  </required_header>
  <id_info>
    <org_study_id>FUSCC-162-9</org_study_id>
    <nct_id>NCT04302441</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Vinorelbine Plus Capecitabine Combined With Trastuzumab for HER2 Positive Patients Following Neoadjuvant Chemotherapy</brief_title>
  <official_title>A Study to Evaluate Vinorelbine Plus Capecitabine Combined With Trastuzumab as the Adjuvant Treatment of HER2 Positive Patients Following Neoadjuvant Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate vinorelbine plus capecitabine combined with trastuzumab versus&#xD;
      trastuzumab alone as the adjuvant Treatment of HER2 positive patients following neoadjuvant&#xD;
      chemotherapy&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 10, 2016</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>3 year</time_frame>
    <description>The length of time after primary treatment for a cancer ends that the patient survives without any signs or symptoms of that cancer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence free survival</measure>
    <time_frame>3 year</time_frame>
    <description>Recurrence free survival is calculated from surgery to the first recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant disease free survival</measure>
    <time_frame>3 year</time_frame>
    <description>Distant disease free survival is calculated from surgery to the first distant metastasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5=3 year</time_frame>
    <description>Overall survival is calculated from randomization to death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">550</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>NXH group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients should receive four cycles of NXH regimen (vinorelbine at 25 mg/m2 iv infusion on day 1 and day 8 plus capecitabine 1000mg/m2, po, bid, d1-d14, 21 days per cycle, trastuzumab at 6mg/kg iv infusion on day1 every 3 weeks to 1 year).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>H group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients should receive trastuzumab at 6mg/kg iv infusion on day1 every 3 weeks to 1 year.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine</intervention_name>
    <description>vinorelbine 25mg/m2 on day 1 and 8,every 3 weeks</description>
    <arm_group_label>NXH group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine 1000mg/m2, po, bid, d1-d14, 21 days per cycle</description>
    <arm_group_label>NXH group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18 and 70 years old&#xD;
&#xD;
          -  Patients with histologically confirmed unilateral invasive ductal carcinoma(according&#xD;
             to WHO histologically type)&#xD;
&#xD;
          -  Tumor clinical staged as IIB-IIIB before neoadjuvant chemotherapy (according to the&#xD;
             7th AJCC edition).&#xD;
&#xD;
          -  After standard treatment (at least 6 cycles) of neoadjuvant chemotherapy (plan&#xD;
             formulated by the attending doctor, including anthracycline and paclitaxel drugs&#xD;
             combined with trastuzumab), assessed by the surgery, the original site for non - pCR&#xD;
             (MP class 1-4) or lymph nodes are still positive for patients.&#xD;
&#xD;
          -  No gross or microscopic tumor residual after resection.&#xD;
&#xD;
          -  Patients with Her2 receptor positive (Specific definition: immunohistochemical&#xD;
             detection of Her2 3+ or Her2 2 + but after FISH or CISH tested is positive).&#xD;
&#xD;
          -  No evidence of distant metastasis in the clinical or radiological aspects of&#xD;
             preoperative. examination,that is M0.&#xD;
&#xD;
          -  Patients without peripheral neuropathy or I peripheral neurotoxicity.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤1.&#xD;
&#xD;
          -  Patients recovered well after surgery, at least 1 weeks after the operation.&#xD;
&#xD;
          -  Adequate marrow: White blood cells count≥3000/μL,neutrophil count ≥1500/μL, hemoglobin&#xD;
             ≥9g/dL and platelet count ≥75000/μL.&#xD;
&#xD;
          -  Normal liver function test: Alanine Aminotransferase (ALT), Aspartate Aminotransferase&#xD;
             (AST) ≤ 1.5×upper limit of normal (ULN) concomitant with alkaline phosphatase (ALP) ≤&#xD;
             2.5×ULN, and bilirubin ≤ 1.5ULN.&#xD;
&#xD;
          -  Adequate renal function: Serum creatinine ≤ 1.5ULN.&#xD;
&#xD;
          -  Contraception during the treatment of child-bearing women.&#xD;
&#xD;
          -  Adequate cardiac function :Left ventricular ejection fraction (LVEF) &gt; 50%.&#xD;
&#xD;
          -  Patients must be informed of the investigational nature of this study and give written&#xD;
             informed consent.&#xD;
&#xD;
          -  Patients without serious heart, lung, liver, kidney and other important organs disease&#xD;
             history.&#xD;
&#xD;
          -  Patients have good compliance.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with bilateral breast cancer or carcinoma in situ(DCIS/LCIS).&#xD;
&#xD;
          -  Metastasis of any part except axillary lymph nodes.&#xD;
&#xD;
          -  Clinical or imaging suspicion of the contralateral breast is malignant but not&#xD;
             confirmed, requiring biopsy.&#xD;
&#xD;
          -  There have been malignant tumors (except for basal cell carcinoma and carcinoma in&#xD;
             situ of cervix) in the last five years, including breast cancer.&#xD;
&#xD;
          -  Patients have been enrolled in other clinical trials.&#xD;
&#xD;
          -  Patients with severe systemic illnesses and/or uncontrolled infections are unable to&#xD;
             join the study.&#xD;
&#xD;
          -  Patients with severe cardio-cerebrovascular disorders (e.g., unstable angina pectoris,&#xD;
             chronic heart failure, uncontrollable hypertension &gt;160/100mmgh, myocardial infarction&#xD;
             or cerebrovascular accident) in the first 6 months of randomization.&#xD;
&#xD;
          -  Pregnant lactating women (child-bearing women must be negative for pregnancy test&#xD;
             within 14 days prior to first delivery, if positive, the pregnancy should be excluded&#xD;
             by ultrasound.)&#xD;
&#xD;
          -  Child-bearing women who are unwilling to take effective contraceptive measures in the&#xD;
             course of research.&#xD;
&#xD;
          -  Patients with mental illness, cognitive impairment, inability to understand test&#xD;
             protocols and side effects, and those who fail to complete the trial programme and&#xD;
             follow-up work (a systematic assessment is required before the trial).&#xD;
&#xD;
          -  Persons without personal freedom and independent civil capacity.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhi-Ming Shao</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhi-Ming Shao, M.D.</last_name>
    <phone>862164175590</phone>
    <phone_ext>862164175590</phone_ext>
    <email>zhimingshao@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhi-Min Shao</last_name>
    <email>zhimingshao@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Breast cancer institute of Fudan University Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhi-Ming Shao, MD</last_name>
      <phone>86-21-641755901105</phone>
      <email>zhimingshao@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 7, 2020</study_first_submitted>
  <study_first_submitted_qc>March 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2020</study_first_posted>
  <last_update_submitted>March 7, 2020</last_update_submitted>
  <last_update_submitted_qc>March 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Zhimin Shao</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>non-pCR</keyword>
  <keyword>HER2 positive</keyword>
  <keyword>vinorelbine</keyword>
  <keyword>capecitabine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

